{
    "clinical_study": {
        "@rank": "147819", 
        "arm_group": [
            {
                "arm_group_label": "LY2157299 (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day."
            }, 
            {
                "arm_group_label": "LY2157299 + Lomustine (Part B)", 
                "arm_group_type": "Experimental", 
                "description": "LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily.\nLomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of oral LY2157299 as monotherapy and in combination with lomustine in\n      participants with recurrent malignant glioma."
        }, 
        "brief_title": "A Dose-Escalation Study in Participants With Recurrent Malignant Glioma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have given written informed consent\n\n          -  Have histological or cytological evidence of relapsed malignant glioma (such as\n             glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma) for\n             which no treatment of higher priority exists\n\n               -  Available baseline tumor specimen is required prior to considering participant\n                  to be enrolled. The original diagnostic tumor tissue is sufficient for this\n                  inclusion criteria, but where possible, freshly obtained tumor biopsy material\n                  may be obtained\n\n               -  Measurable disease to allow assessment of tumor response based on radiographic\n                  assessment following Macdonald criteria and Response Evaluation Criteria In\n                  Solid Tumors (RECIST)\n\n          -  Have sufficient hepatic, renal, and hematological function\n\n          -  Have a performance status of \u22642 on the Eastern Cooperative Oncology Group (ECOG)\n             scale\n\n          -  Have discontinued all previous therapies for cancer, including chemotherapy,\n             radiotherapy  or other investigational therapy for at least 30 days prior to study\n             enrollment and recovered from the acute effects of therapy\n\n          -  Able to swallow tablets and capsules\n\n          -  For females, reproductive potential must be either terminated (by surgery, radiation,\n             or menopause) or attenuated by the use of an approved contraceptive method (including\n             intrauterine or barrier devices) during and for 3 to 6 months after the study\n\n          -  Male participants must be willing to use contraception during and for 3 to 6 months\n             after the study\n\n        Exclusion Criteria:\n\n          -  Have received treatment within the last 30 days with a drug that has not received\n             regulatory approval for any indication at the time of study entry\n\n          -  Have moderate or severe cardiac disease:\n\n               -  Have the presence of cardiac disease, including a myocardial infarction within 6\n                  months prior to study entry, unstable angina pectoris, New York Heart\n                  Association (NYHA) Class III/IV congestive heart failure, or uncontrolled\n                  hypertension\n\n               -  Have documented major electrocardiogram (ECG) abnormalities at the\n                  investigator's discretion (for example, symptomatic or sustained atrial or\n                  ventricular arrhythmias, second- or third-degree atrioventricular block, bundle\n                  branch blocks, ventricular hypertrophy, or recent myocardial infarction)\n\n               -  Have major abnormalities documented by echocardiography with Doppler (for\n                  example, moderate or severe heart valve function defect and/or left ventricular\n                  ejection fraction (LVEF) <50%, evaluation based on the institutional lower limit\n                  of normal)\n\n               -  Have predisposing conditions that are consistent with development of aneurysms\n                  of the ascending aorta or aortic stress (for example, family history of\n                  aneurysms, Marfan syndrome, bicuspid aortic valve, evidence of damage to the\n                  large vessels of the heart documented by computerized tomography [CT] scan  with\n                  contrast)\n\n          -  Have current acute or chronic leukemia\n\n          -  Women who are pregnant or lactating\n\n          -  Have received prior nitrosourea (including lomustine) therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682187", 
            "org_study_id": "8660", 
            "secondary_id": "H9H-MC-JBAH"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2157299 (Part A)", 
                    "LY2157299 + Lomustine (Part B)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "LY2157299", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY2157299 + Lomustine (Part B)", 
                "description": "Administered orally", 
                "intervention_name": "Lomustine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lomustine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Recommended Dose for Phase 2 Studies", 
            "safety_issue": "Yes", 
            "time_frame": "Time of first dose to time of last dose (estimated up to 8 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants with Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "Time of first dose to time of last dose (estimated up to 8 years)"
            }, 
            {
                "measure": "Biologically Effective Dose Range", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Days 1, 12, 13 of Cycle 1, Days 1 and 12 of Cycle 2 of Part A - LY2157299 as monotherapy"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Part A Cycle 1: predose, up to 6 hours on Days 1, 3, 6, 12, 13, and 14; Part A Cycle 2: predose up to 6 hours on Days 1, 12, and 13. Part B Cycle 1: predose up to 6 hours on Days 1, 6, 7, 10, 12, 13, and 14"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Part A Cycle 1: predose, up to 6 hours on Days 1, 3, 6, 12, 13, and 14; Part A Cycle 2: predose up to 6 hours on Days 1, 12, and 13. Part B Cycle 1: predose up to 6 hours on Days 1, 6, 7, 10, 12, 13, and 14"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2005", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}